A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers

作者：Leggio Lorenzo^*; Zywiak William H; Edwards Steven M; Tidey Jennifer W; Swift Robert M; Kenna George A

来源：Psychopharmacology, 2015, 232(1): 233-243.

DOI：10.1007/s00213-014-3652-9

• Baclofen
• Alcoholism
• Smoking
• Comorbidity

There is presently no approved single treatment for dual alcohol and nicotine dependencies.
This pilot study investigated baclofen effects in alcoholic smokers.
This was a preliminary double-blind placebo-controlled randomized clinical study with 30 alcoholic smokers randomized to baclofen at 80 mg/day or placebo. A subgroup (n = 18) participated in an alcohol cue-reactivity experiment.
Baclofen, compared with placebo, significantly decreased the percent days of abstinence from alcohol-tobacco co-use (p = 0.004). Alcohol dependence severity moderated baclofen effects, with the higher severity group having the greater baclofen response (p < 0.001). Although the percent days of alcohol-tobacco co-use declined in both groups, this decline was greater after placebo than baclofen (p < 0.001). Secondary analyses on alcohol or tobacco use alone suggested that the increase in percent days of co-abstinence was driven by the medication differences on heavy drinking days and on percent days smoking. In the cue-reactivity substudy, baclofen slightly decreased alcohol urge (p = 0.058) and significantly reduced salivation (p = 0.001), but these effects were not related to cue type.
This study provides preliminary evidence suggesting a possible role of baclofen in the treatment of alcoholic smokers. However, the mixed results and the small sample require larger confirmatory studies.

• 出版日期2015-1